<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5D7F6813-A83D-41F3-A308-3B162C7DFCA1"><gtr:id>5D7F6813-A83D-41F3-A308-3B162C7DFCA1</gtr:id><gtr:name>National Brain Research Centre, India</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/04F74C3C-A421-45EF-958F-903BE8464FA7"><gtr:id>04F74C3C-A421-45EF-958F-903BE8464FA7</gtr:id><gtr:name>Accretion Biotechnology Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DD698BE9-1ED7-42BF-AC5D-427A5CA5851D"><gtr:id>DD698BE9-1ED7-42BF-AC5D-427A5CA5851D</gtr:id><gtr:name>Bayer</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/80392F0C-23A4-449D-BC8D-4D77C0F53303"><gtr:id>80392F0C-23A4-449D-BC8D-4D77C0F53303</gtr:id><gtr:name>Mahidol University</gtr:name><gtr:address><gtr:line1>Mahidol University</gtr:line1><gtr:line2>Office of the President  Mahidol Univers</gtr:line2><gtr:line3>25/25 Moo 3, Phuttamonthon 4 Road</gtr:line3><gtr:postCode>73170</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5D7F6813-A83D-41F3-A308-3B162C7DFCA1"><gtr:id>5D7F6813-A83D-41F3-A308-3B162C7DFCA1</gtr:id><gtr:name>National Brain Research Centre, India</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/04F74C3C-A421-45EF-958F-903BE8464FA7"><gtr:id>04F74C3C-A421-45EF-958F-903BE8464FA7</gtr:id><gtr:name>Accretion Biotechnology Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DD698BE9-1ED7-42BF-AC5D-427A5CA5851D"><gtr:id>DD698BE9-1ED7-42BF-AC5D-427A5CA5851D</gtr:id><gtr:name>Bayer</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/80392F0C-23A4-449D-BC8D-4D77C0F53303"><gtr:id>80392F0C-23A4-449D-BC8D-4D77C0F53303</gtr:id><gtr:name>Mahidol University</gtr:name><gtr:address><gtr:line1>Mahidol University</gtr:line1><gtr:line2>Office of the President  Mahidol Univers</gtr:line2><gtr:line3>25/25 Moo 3, Phuttamonthon 4 Road</gtr:line3><gtr:postCode>73170</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D755320B-897A-4664-984C-1480D6978A96"><gtr:id>D755320B-897A-4664-984C-1480D6978A96</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:surname>Lechler</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_14105"><gtr:id>63E4C52A-78CA-4A21-8490-2E231CAACBB0</gtr:id><gtr:title>King's Health Partners Confidence in Concept</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_14105</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2016-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>650000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Brain Research Centre, India</gtr:collaboratingOrganisation><gtr:country>India, Republic of</gtr:country><gtr:description>Collaboration with NBRC, India</gtr:description><gtr:id>AF6F8385-55AD-4FE4-82D6-CE6582453BC1</gtr:id><gtr:impact>No outputs yet</gtr:impact><gtr:outcomeId>56e03278ec2315.11848072-1</gtr:outcomeId><gtr:partnerContribution>Contributed to the funding application and identified the postdoctoral fellow.</gtr:partnerContribution><gtr:piContribution>Applied for funding to host a postdoctoral fellow funded by the Newton International fellowship scheme of the Academy of Medical Sciences, UK.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Accretion Biotechnology Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with Accretion biotechnology Ltd</gtr:description><gtr:id>FCDCB5FD-F3DF-4363-82DF-AF05B4282458</gtr:id><gtr:impact>The collaboration is multidisciplinary:

KCL provides: Biologist, chemists, clinical scientists

Accretion Biotechnology provide: Business development</gtr:impact><gtr:outcomeId>56dee56e5d9b16.81593432-1</gtr:outcomeId><gtr:partnerContribution>Accretion Biotechnology have licensed the KCL Patent for 68Ga-CP256-PSMA in return
for providing a Gallium generator, funding a PhD student, milestone payments and
building a commercial network to facilitate product development, manufacture and
marketing of the tracer.</gtr:partnerContribution><gtr:piContribution>We are in the process of collecting data to provide information on whether the tracer can be used to evaluate response of prostate cancer to chemotherapy in a mouse model. It is hoped that this will provide pre-clinical data for a clinical trial which will facilitate marketing of the tracer for clinical use for response to therapy. Additionally, Prof. Philip Blower (Co-investigator) is the primary supervisor of the PhD student supported by the collaborator. The research team have demonstrated that the tracer accumulates specifically in PSMA positive prostate cancer xenografts.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bayer</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Bayer HealthCare</gtr:department><gtr:description>Bayer</gtr:description><gtr:id>BEB55EB0-5036-4E3E-90B8-34DD0E3290DF</gtr:id><gtr:impact>Grant funding has been achieved.</gtr:impact><gtr:outcomeId>567a9f0b6bee16.18936639-1</gtr:outcomeId><gtr:partnerContribution>Bayer HC have provided know how and input into several aspects of the project, notably microarray analysis of expanded cells.</gtr:partnerContribution><gtr:piContribution>We are working with Bayer HC to develop adoptive immunotherapeutic strategies for triple negative breast cancer using ex-vivo expanded gamma delta T-cells.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Public Health England</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PHE Collab</gtr:description><gtr:id>50953A34-893A-4FA6-A28A-F4D583DD97E5</gtr:id><gtr:impact>none as yet, publications in preparation</gtr:impact><gtr:outcomeId>58c7b77aacbf17.88456760-1</gtr:outcomeId><gtr:partnerContribution>Access to samples for Sierra Leone Ebola outbreak</gtr:partnerContribution><gtr:piContribution>Proposed to host joint PhD studentships</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mahidol University</gtr:collaboratingOrganisation><gtr:country>Thailand, Kingdom of</gtr:country><gtr:department>Siriraj Hospital</gtr:department><gtr:description>UK Thai collaboration</gtr:description><gtr:id>44B13FAC-98BA-4921-B932-CF12307F76F4</gtr:id><gtr:impact>There have been no defined outputs as yet although the collaboration is at a very early stage.</gtr:impact><gtr:outcomeId>57c46b5a4678e5.22986530-1</gtr:outcomeId><gtr:partnerContribution>Prof Yenchitsomanus's group has offered us access to a human antibody library from which new CAR targeting moieties may be isolated. These plans are currently at an early stage and will be advanced following our next meeting in October.</gtr:partnerContribution><gtr:piContribution>Over the past 6 months, I have begun to collaborate with that of Prof Pa-thai Yenchitsomanus in Bangkok in the area of CAR T-cell immunotherapy. My group has contributed know-how and plasmid reagents to support the development of novel CARs targeted against the MUC1 mucin and other solid tumour targets. I have also supported a fellowship application by one of the senior members of Prof Yenchitsomanus's group. In June, I visited the group of Prof Yenchitsomanus in Bangkok and have presented at two conferences there at which group members were also present. I look forward to hosting Prof Yenchitsomanus and a delegation from his group on a visit to London in October at which we will share research data and plan for further collaborations in this area.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>European Conference of Immunology, Vienna 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5F037C21-17E4-4641-B7ED-767D8D148F45</gtr:id><gtr:impact>Accepted abstract at the European Conference of Immunology in the Category of Innate lymphocytes. The accepted poster described the research project, human tissue resident gamma delta T cell biology, their innate potential, the unidentified tissue checkpoint and their response to tissue disassociation. The poster was well received and generated discussion. One industrial representative asked for possible collaboration using laser induced delivery of molecules under sterile conditions within the human dermis in vitro. Dr. Mathias Eberl from the University of Cardiff suggested a collaboration on tissue resident gamma delta T cells and their role in TH2 skewing of CD4 Helper cells; this would complement published data on cytokine influences on gamma delta T cells very well, we are currently starting to phenotype and identify the specific subset of gamma delta T cells that are of interest to Dr. Eberl in order to confirm feasibility and POC of a possible collaboration. We further established a collaboration with the Kabelitz laboratory at the University of Kiel which will provide us with Hybridoma cell lines producing monoclonal antibodies against various human V gamma chains. Those antibodies are not commercially available and will help us to further describe tissue resident gamma delta T cells in diseased and healthy tissue sections. In general there was very positive feedback from a knowledgeable audience concerning the opportunities that may arise from our novel expansion method.</gtr:impact><gtr:outcomeId>56d5d69b77ee79.96883309</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>http://www.eci-vienna2015.org/images/docs/ECI2015_Abstract-Book-v2.pdf</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>7th biannual Gamma Delta T cell Conference, London 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5185D834-C70D-41FC-AC8B-F8E2D86E2F51</gtr:id><gtr:impact>We are organising the 7th international Gamma Delta T cell conference, taking place at King's College London in June 2016. We are expecting between 300-350 international participants including the leading experts in gamma delta T cell biology. The British Society of Immunology will feature the meeting prominently and Nature Immunology has announced to be present at the meeting. We are planning to present data funded by the MRC confidence in concept grant. One talk will focus on tissue resident human gamma delta T cells, their biology and cross talk with stromal cells, which has helped identify a possibly novel checkpoint inhibitor molecule controlling cytotoxic activity by gamma delta T cells. In the second talk, we will present our newly developed isolation and expansion method to grow tissue derived gamma delta T cells to large numbers ex vivo under optimised growth conditions, which was further developed with the help of MRC funding. Availability of gamma delta T cells for immunotherapy is novel and exciting and may open the door for further collaboration in the immunotherapy field and CAR T cell field.</gtr:impact><gtr:outcomeId>56d5da4b085f48.29970437</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>http://www.gammadelta2016.uk</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Children's Heart Charity Family Day Support (Essex)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>0C359140-598B-485A-93F3-4A74D810D6FC</gtr:id><gtr:impact>Evelina Children's Heart Organisation held an annual family day. My role was to give a talk on our research, the impact it is having worldwide and how the families have been involved. We also ran an exhibition at this event. Over 200 people attended.</gtr:impact><gtr:outcomeId>56e0dfd0292c85.39208258</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Ada Lovelace</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>291DAF56-F4D6-40A2-87B4-046EA111B1C5</gtr:id><gtr:impact>This event is aimed at highlighting female scientists and their work as well as promoting discussion of gender equality in the sciences. 
Ada Lovelace Day event featured talks from myself, Dr Maggie Aderin-Pocock, space scientist and presenter of The Sky at Night and Professor Paul Walton, of the Department of Chemistry at the University of York and long-time champion of equality in the sciences, will talk about gender equality issues in science. This was followed by a panel discussion about gender issues in science and academia and the event ended with a networking and poster session, at which PhD students presented their research.</gtr:impact><gtr:outcomeId>56e057f8c89bb8.10255217</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>http://www.kcl.ac.uk/nms/eventrecords/Ada-Lovelace-Day-2015.aspx</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>GSTT MRes/PhD Programme in Biomedical and Translational Science Public engagement lecture series &amp; MRC-DTP</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>EF131BA2-8908-4F99-8E5F-6C3BAB99E1E4</gtr:id><gtr:impact>Our master's and PhD student cohort listened to individuals from the government select committee on science policy, publishers, biotech industry and clinical trial managers, public engagement experts from the charity sector and academia as well as public heath experts and an individual from the armed forces. The audience typically reached 50 individuals over six one hour sessions.</gtr:impact><gtr:outcomeId>56ddc681ce4e68.58150008</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NASMR</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>09A5DBEF-0117-4F75-A716-7C1306B504CB</gtr:id><gtr:impact>Webcast for NASMR to highlight research intercalated BSc at KCL in immunobiology</gtr:impact><gtr:outcomeId>58c7db9fd9a574.62404931</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lobby Event to raise politicians awareness of heart research funding (Westminster)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7DEFC873-6087-4805-B3B2-A60EB30EE9EE</gtr:id><gtr:impact>BHF event/ exhibition to lobby support in westminster for cardiovascular research</gtr:impact><gtr:outcomeId>56e0e212796952.33984724</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International Congress of Immunology, Melbourne 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1590619A-2BAE-4268-83CB-14E170538A80</gtr:id><gtr:impact>We have submitted an abstract for oral presentation to the international Conference of Immunology in Melbourne in August 2016. Ever since the publication by Gentles et. al reporting their recent analysis (published in Nature Medicine) of 18,000 cancer patients (the largest such sampling ever to be undertaken) which revealed that a gamma delta T cell signature was the strongest positive prognostic indicator across 39 different tumour types, their is an immense interest in using human gamma delta T cells for adaptive immunotherapy or to identify specific ligands for their activation in situ. To our knowledge, because of their elusive numbers in human blood and the lack of extraction protocols from human tissue, we are the only lab capable of isolating, activating and expanding human tissue derived gamma delta T cells to large numbers. Furthermore we plan to report on their cytotoxic behaviour towards transformed cells which are partially mediated via NKG2D. We are optimistic that our request for an oral presentation will be accepted and that our findings will generate positive feedback with the field of basic immunology and applied immunotherapy.</gtr:impact><gtr:outcomeId>56d5d8a0215109.01786819</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>http://ici2016.org/call-for-abstracts/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Channel 5 interview</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4BE6D84D-031E-4C9A-99CA-9542DE519214</gtr:id><gtr:impact>Interview on Channel 5 about the Zika outbreak in Brazil</gtr:impact><gtr:outcomeId>58c7db01549bb7.99313895</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Undergraduate lab visits/job shadowing</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C4FD4A04-BC94-4A1E-9393-852E6F1C8FC9</gtr:id><gtr:impact>2 groups of 2 Chemistry undergraduates visited our laboratories to observe our research. They spent 2 days observing me undertaking pre-clinical scanning on this project and the premise of the research project was explained to them. The students were engaged and asked questions about the research and also about studying for a PhD and subsequent career paths. The students expressed an interest in going on to study for a PhD.</gtr:impact><gtr:outcomeId>56dd778e36e513.59843852</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Bench to bedside video</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E1E67688-9EE6-4B8E-A7AE-36A50E7D47B5</gtr:id><gtr:impact>The goal of this project was to educate students in the contributions that the individual sciences make to healthcare and health sciences. The project was institution wide and stemmed from a presetation I was previously involved with to a teachers conference on the same theme. In my segement I discuss chemistry in general but also the kinds of research we do and how it contributes to health sciences.</gtr:impact><gtr:outcomeId>56e03df0bef894.59249899</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.kcl.ac.uk/study/bench-to-bedside/chemistry.aspx</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>40114</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Graduate Teaching Assistant (GTA) PhD studentship</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>King's College London</gtr:fundingOrg><gtr:id>4AE16472-7C60-435D-9B80-33763C06B764</gtr:id><gtr:outcomeId>56e05404f2a699.50614814</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2718040</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Stratifying Chronic Pain Patients By Pathological Mechanism- A Multimodal Investigation Using Functional MRI, Psychometric And Clinical Assessment</gtr:description><gtr:end>2021-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/N026969/1</gtr:fundingRef><gtr:id>1DE3C0E0-6342-40C8-9ECB-1772A0B032FC</gtr:id><gtr:outcomeId>58c9cc340054a0.01305569</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>501608</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Multidisciplinary Project Award Application Title: Integrating medical imaging into cancer immunotherapy: Development of clinically traceable CAR and GammaDelta T-cells</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C48390/A21153</gtr:fundingRef><gtr:id>060A1D1D-515E-4B51-ADB0-5788AC0696CE</gtr:id><gtr:outcomeId>58b5711469e876.05075950</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>26860</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Identifying hypoxia-mediated effects on breast cancer invasion in vivo.</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>Breast Cancer Now</gtr:fundingOrg><gtr:id>B15424BC-6E31-4EF3-81FD-31191F28120C</gtr:id><gtr:outcomeId>58c85017e7e5b3.71830037</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>69477</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Drug Discovery Committee - Biotherapeutics Drug Discovery Project Award</gtr:description><gtr:end>2019-08-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C11499/A21623</gtr:fundingRef><gtr:id>F11E2262-9F3C-40F2-93D6-8959208A541D</gtr:id><gtr:outcomeId>58b56fd37702a9.65458497</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre (Guy's, St Thomas' and KCL)</gtr:department><gtr:description>PhD studentship</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>D7ACF9C4-4AB2-4034-A775-9D7126DDFF9F</gtr:id><gtr:outcomeId>58b5600b8b7165.08885779</gtr:outcomeId><gtr:sector>Hospitals</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>King's Biosciences studentship</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>King's College London</gtr:fundingOrg><gtr:id>009F0836-6C5A-4ECC-BEC6-2B60F018DE24</gtr:id><gtr:outcomeId>58c7bac39520c6.18903040</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>211718</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The relation of cerebral oxygen delivery to brain dysmaturation and damage in infants with congenital heart disease</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>FS/15/55/31649</gtr:fundingRef><gtr:id>94CC0A56-936A-44BB-BD97-794679A41683</gtr:id><gtr:outcomeId>58c2d9b3eabc25.49080684</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>224404</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Biotherapeutics Drug Discovery project</gtr:description><gtr:end>2018-11-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>65B5C140-090A-45B7-9812-C8B091B22EFA</gtr:id><gtr:outcomeId>56def66d252bd1.15384752</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Marie Curie Postdoctoral fellowship</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>European Research Council (ERC)</gtr:fundingOrg><gtr:fundingRef>750621</gtr:fundingRef><gtr:id>F996A011-824D-4610-B6FF-D5FCF93B39CF</gtr:id><gtr:outcomeId>58c7b8fbadb7e7.52018819</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>452468</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The Resilient Brain. Imaging Biomarkers of Brain Metabolic Reserve</gtr:description><gtr:end>2019-11-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/N009088/1</gtr:fundingRef><gtr:id>67C5DE28-CBFF-453E-BCF6-513B60B196E4</gtr:id><gtr:outcomeId>58c2da9b5ad3f6.65295345</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>170479</gtr:amountPounds><gtr:country>Unknown</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Integrating Imaging into Immunotherapy - Developing PET traceable CAR T-cells.</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>Worldwide Cancer Research</gtr:fundingOrg><gtr:id>D0AA6037-27B7-41F1-8CE0-3BDA16374860</gtr:id><gtr:outcomeId>58c84fa8398e61.38632245</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>King's Biosciences studentship</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>King's College London</gtr:fundingOrg><gtr:id>3505BF85-F72D-4092-8838-A54F3DE6138C</gtr:id><gtr:outcomeId>58c7ba86b3e196.09410637</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2019-02-02</gtr:end><gtr:fundingOrg>Bernice Bibby Research Trust</gtr:fundingOrg><gtr:id>6E09421A-81E2-4E4C-B2E7-2DC948EE5510</gtr:id><gtr:outcomeId>58b55fb7b94754.30685680</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>501608</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Integrating medical imaging into cancer immunotherapy: Development of clinically traceable CAR and GammaDelta T-cells</gtr:description><gtr:end>2019-06-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>21153</gtr:fundingRef><gtr:id>787F4309-C213-4ED5-AB92-26F8AB6203D6</gtr:id><gtr:outcomeId>58c84f1806f230.31712423</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Discovery Award</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MC_PC_15068</gtr:fundingRef><gtr:id>5C19920C-C9F0-424B-B8A1-4C7155F50306</gtr:id><gtr:outcomeId>56e18fcce3a5a5.06216274</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>775000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Translation Fund</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>9FD616FB-EF8C-4B8F-8BCF-2D8D0852C3C8</gtr:id><gtr:outcomeId>5430fa4eeba6d9.38750731</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>762000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>SRA with GammDelta Therapeutics</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>GammaDelta Therapeutics Ltd</gtr:fundingOrg><gtr:id>920A830A-462B-4641-9CDD-ED9934A26E45</gtr:id><gtr:outcomeId>58c6be55b45501.11777807</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>501608</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Multidisciplinary project award</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>275318A9-7C64-420B-9F9F-2FBBDCD3B02C</gtr:id><gtr:outcomeId>56deeca9e60f27.38526373</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>detection of early stage heart failure</gtr:description><gtr:grantRef>MC_PC_14105</gtr:grantRef><gtr:id>3F9F8F42-ED2F-4767-AE71-AF0800D4FFED</gtr:id><gtr:impact>None yet</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>58b82a2b61ad78.60564573</gtr:outcomeId><gtr:patentId>GB1603216.1</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Measurement of cardiac first phase ejection fraction</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>This patent describes a novel CAR platform known as a parallel CAR in which synergistic T-cell activating signals are delivered by two chimeric receptors with complementary endodomains. Exemplification is provided by a number of examples including pCARs targeted against CSF-1R, avb6 integrin and ErbB receptor tyrosine kinases.</gtr:description><gtr:grantRef>MC_PC_14105</gtr:grantRef><gtr:id>849B780F-F573-4183-98D7-9BF327DE9FA9</gtr:id><gtr:impact>PCT just published</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>58b572b2665ef8.75337782</gtr:outcomeId><gtr:patentId>WO 2017/021701 A1</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Therapeutic agents</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells</gtr:description><gtr:grantRef>MC_PC_14105</gtr:grantRef><gtr:id>2F4EB3DF-3A89-4EE6-B9F4-667D8855EA0E</gtr:id><gtr:impact>Formation of spinout</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>58c2e21cdaad01.79891198</gtr:outcomeId><gtr:protection>Patent application published</gtr:protection><gtr:title>Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention relates to a method for expanding non-haematopoietic tissue-resident ?d T cells ex vivo. The term &amp;quot;non-haematopoietic tissue-resident ?d T cells&amp;quot; refers to subsets of T lymphocytes that reside within non-haematopoietic tissues, rather than within lymphoid organs and blood. Such cells include non-Vd2 cells, e.g. Vd1, Vd3 and Vd5 cells. The invention also relates to the use of these cells in adoptive T cell therapy and in chimeric antigen receptor therapy, as well as their use in a method of screening for checkpoint modulators. The invention also relates to the cells produced as a result of ex vivo expansion of non-haematopoietic tissue-resident ?d T cells.</gtr:description><gtr:grantRef>MC_PC_14105</gtr:grantRef><gtr:id>DAF6886F-3E36-40AD-8B64-1880EAA53B18</gtr:id><gtr:impact>This patent application is co-owned by King's College London, Cancer Research Technologies and The Francis Crick Institute. It has been licensed to the London based Start-Up Company GammaDelta Therapeutics Ltd. of which King's College London is a founding Institution.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>58c6bc48181837.52231670</gtr:outcomeId><gtr:patentId>PCT/EP2016/076264</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>EXPANSION OF NON-HAEMATOPOIETIC TISSUE-RESIDENT ? d T CELLS AND USES OF THESE CELLS</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Method 1: By isolating cell surface proteins from HFF cells and performing an IP using whole primary gamma delta 1 T cells, before performing a series of elutions, we will isolate proteins which interact with gamma deltas in a physiologically relevant manner. These proteins will then be sent for mass spec. analysis. The resulting qualitative and quantitative data will inform our choice of check point candidate.
Method 2: By crosslinking and isolating the cell surface proteome of gamma delta 1 T cells we will IP the CD3 TCR complex using an anti CD3zeta antibody. This will be used as a probe to futher IP the interacting protein from the HFF cell surface proteome isolate. The protein of interest will be sent for mass spec. analysis, with the resulting data informing us of the TCR interacting protein(s).</gtr:description><gtr:id>31A7FABD-1762-41A9-8143-66BC17FBF44C</gtr:id><gtr:impact>One of the aims of this work is to to identify a novel checkpoint for gamma delta 1s. The observation that the interaction between delta 1 s and fibroblasts inhibits expansion / activation suggests such a checkpoint exists in this system. Inhibition of this 'de-activation' may be beneficial for anti-cancer immunotherapeutic techniques involving these cells, in a similar manner to PD1 or CTLA4.</gtr:impact><gtr:outcomeId>56deac7e296aa6.30590089</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Isolation and identification of fibroblast derived gamma delta interacting proteins</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A new plasmid DNA was created to enable virus-mediated genetic engineering of primary human T-cells to express a chimeric antigen receptor together with a radionuclide-fluorescence dual-mode reporter gene; the latter is intended for in vivo tracking of engineered cellular therapeutics (in preclinical models)</gtr:description><gtr:id>17574C52-2185-4B2C-ABA7-100BD75FDF7A</gtr:id><gtr:impact>This tool enables in vivo cell tracking of all CAR T-cell therapeutics by radionuclide-fluorescence imaging in preclinical in vivo models. It contributes to the development of such therapeutics.</gtr:impact><gtr:outcomeId>58c84d71ef4687.27814837</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Viral CAR::Reporter plasmid for preclinical dual-mode in vivo imaging</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have established CRISPR plasmids to allow us to knock out specific genes or interest in human fibroblast cell lines. We have identified specific cross talk between human dermal fibroblasts and tissue resident gamma delta T cells. We undertook several experiments ruling out classic checkpoint control molecules such as B7 like molecules, CTLA4, LAG3, TIM3 for which staining and blocking reagents are available. As none of these candidates showed any influence on gamma delta T cell biology, we required CRISPR technology to knock out specific proteins of interest, such as newly emerging immunosuppressive molecules such as TIGIT-PVR. To date we have established CRISPR and applied it to generate 3 different human fibroblast knock out lines which we are currently testing in co cultures with stimulated human tissue derived gamma delta T cells.</gtr:description><gtr:id>63AD0CF1-7ADB-4D5B-AAA2-2EF5B56F89D5</gtr:id><gtr:impact>As counterparts for human gamma delta T cells do not directly exist in mice we need strong ex-vivo/in vitro assays to study gamma delta T cell behaviour closely resembling the in-situ situation. We have previously established a co culture of human fibroblast lines and tissue derived gamma delta T cells showing that in direct contact with dermal fibroblasts, gamma delta T cells remain inactive and display a similar phenotype to those directly isolated from tissue. With the use of CRISPR we can now manipulate single proteins, hopefully identifying molecules involved in tissue homoeostasis and checkpoint control inhibition that are not yet known with possible direct implications for translational science and immunotherapy.</gtr:impact><gtr:outcomeId>56d5dd41c153f5.57685251</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>CRISPR knock out human fibroblast cell lines</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have previously identified mechanisms of tissue damage and dissociation which cause downstream activation of tissue resident gamma delta T cells. This allows for the first time for the isolation and expansion of human tissue resident gamma delta T cells. As part of this grant proposal we aimed to optimise the expansion of gamma delta T cells by testing 20 different chemokines, cytokines and growth factors to support and co stimulate gamma delta T cell expansion. Whilst extensive testing is still undergoing we have identified two candidate cytokines so far which support gamma delta T cell growth specifically, allowing for even greater expansion of these cells than we initially achieved with the support of IL-2 only. We are confident that via additional combinations of additional cytokines we can boost this effect even further reaching large scale expansion suitable for clinical application. Currently we are able to expand up to 10 to the 8 tissue derived gamma delta T cells per donor. Once the ideal cocktail has been identified, we aim to test these conditions in growth media supplemented with human serum, and ideally in serum free conditions, in appropriate culture systems, preparing the ground for GMP concordant expansion of tissue derive gamma delta T cells.</gtr:description><gtr:id>28C584E6-E1B4-4363-8036-482C01D637E4</gtr:id><gtr:impact>There is great interest from research groups and industry to use human gamma delta T cells for adaptive immunotherapy as well as CAR T cell technology. Our newly developed and optimised protocols allow, for the first time, the expansion of tissue derived gamma delta T cells to clinically relevant numbers. This in vitro expansion system will also allow us to further explore the biology of these cells enabling us to identify ligands for these unconventional T cells - which are MHC unrestricted and do not recognise peptide antigens. This will generate vast interest in the immunological research community, and may ultimately lead to the development of a novel tissue derived gamma delta T cell check point therapy.</gtr:impact><gtr:outcomeId>56d5dfd6e19fc6.80661269</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Enhanced cytokine mediated gamma delta T cell expansion</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have already obtained thymic tissues taken from two children undergoing cardiac surgery. We have characterised the T cell composition of these samples and have purified Tregs by fluorescence activated cell sorting using established strategies applied to peripheral blood Tregs (CD4, CD25 and CD127). Thymic Tregs were then expanded polyclonally. Additionally, sorted Treg populations have also been preserved to analyse TSDR methylation status (a measure of FOXP3 stability) and TCR diversity using RNAseq approaches.</gtr:description><gtr:id>E2AB975D-8C39-403E-9920-846F3848A8C1</gtr:id><gtr:impact>Development of a potential clinical application for heart transplantation.</gtr:impact><gtr:outcomeId>56e0e491ba2021.66196003</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Purification and Expansion of Explanted thymic T-regs</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>GammaDelta Therapeutics Ltd.</gtr:companyName><gtr:description>GammaDelta Therapeutics is focused on turning a breakthrough in the extraction and amplification of tissue-resident gamma-delta T cells into a pipeline of programs that can invade solid tumors more effectively than existing options.</gtr:description><gtr:id>104256C1-0BBA-4057-B136-A29BDE1F4A5F</gtr:id><gtr:impact>GammaDelta Therapeutics has received seed funding from the London based VC Abingworth and hast started its R&amp;amp;D program and translational work with a focus on GMP cell production. It currently employs 4 FTE scientists and is looking to increase this numbers to 12 by the end of 2017 whilst negotiating series A funding.</gtr:impact><gtr:outcomeId>58c6ba1ae67f18.66542672</gtr:outcomeId><gtr:url>http://www.fiercebiotech.com/biotech/embargoed-until-19-01-edt-abingworth-seeds-i-o-startup-to-exploit-advance-solid-tumor</gtr:url><gtr:yearCompanyFormed>2016</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>85035E2B-4EFF-4B84-BD9F-586EFE223491</gtr:id><gtr:title>The opposing effect of environmental &amp;amp; dietary modification vs. stress on brain activity and cognition in rats.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7646aa126b46d37924f8b97bccb3fbaf"><gtr:id>7646aa126b46d37924f8b97bccb3fbaf</gtr:id><gtr:otherNames>Simmons, C.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58c2dd9b49e2d3.52773392</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C650A4E0-A75E-4137-B14E-DEC040D3F225</gtr:id><gtr:title>Targeting of Aberrant av?6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26df6ecbbfa25d74e3babc1f779db156"><gtr:id>26df6ecbbfa25d74e3babc1f779db156</gtr:id><gtr:otherNames>Whilding LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>5a34eb661c2594.93768610</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6FFC054-C8B0-46FC-BB13-498EBABD1AC0</gtr:id><gtr:title>Treg therapy in transplantation: a general overview.</gtr:title><gtr:parentPublicationTitle>Transplant international : official journal of the European Society for Organ Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32ae8244d7b23002c2b8fee8ecc0bf07"><gtr:id>32ae8244d7b23002c2b8fee8ecc0bf07</gtr:id><gtr:otherNames>Romano M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0934-0874</gtr:issn><gtr:outcomeId>58b58b3dd1a6a9.28001539</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2FD969A4-ADA4-4A6F-B0F3-F2FF6162FA43</gtr:id><gtr:title>Fascin Regulates Nuclear Movement and Deformation in Migrating Cells.</gtr:title><gtr:parentPublicationTitle>Developmental cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a531677aec2dbc5c6dc8843ca7458efd"><gtr:id>a531677aec2dbc5c6dc8843ca7458efd</gtr:id><gtr:otherNames>Jayo A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1534-5807</gtr:issn><gtr:outcomeId>585d3425563889.34997402</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4464C77-71C7-4F9C-9C8D-B007B2FFC2ED</gtr:id><gtr:title>Network-Informed Gene Ranking Tackles Genetic Heterogeneity in Exome-Sequencing Studies of Monogenic Disease.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04ff31364b21b3d0ea05149a98ee8ac7"><gtr:id>04ff31364b21b3d0ea05149a98ee8ac7</gtr:id><gtr:otherNames>Dand N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>56bdf46716d8b4.33523528</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DAFECFA-DBBC-4A76-9020-C0137C88E53F</gtr:id><gtr:title>Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40ce2d2d8f45c6b90334b20d220ab1ac"><gtr:id>40ce2d2d8f45c6b90334b20d220ab1ac</gtr:id><gtr:otherNames>Foglia E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>58c81e9624c949.58563439</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A77826FF-BE4F-4779-AAC9-55FBB2BCB69A</gtr:id><gtr:title>Regulatory T cells: tolerance induction in solid organ transplantation.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e40ea6a39fae2baf5393f722dd9d371"><gtr:id>3e40ea6a39fae2baf5393f722dd9d371</gtr:id><gtr:otherNames>Vaikunthanathan T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>5a900e327cb702.40512567</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B939BAF6-6631-4C9F-A5B3-6265BB08A5B5</gtr:id><gtr:title>Ga-THP-PSMA: A PET Imaging Agent for Prostate Cancer Offering Rapid, Room-Temperature, 1-Step Kit-Based Radiolabeling.</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36b0186a9ac6403dc98071701a7b731a"><gtr:id>36b0186a9ac6403dc98071701a7b731a</gtr:id><gtr:otherNames>Young JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn><gtr:outcomeId>5aa948868ceef5.75647604</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F3E5E49-9EE8-4970-8ABB-7B113817A59C</gtr:id><gtr:title>Antipsychotic efficacy in psychosis with co-morbid cannabis misuse: A systematic review.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4bb42d39c387ce1f1b78fcda938784b8"><gtr:id>4bb42d39c387ce1f1b78fcda938784b8</gtr:id><gtr:otherNames>Wilson RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>56d1fce561e500.00458832</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1549C06-135B-4E0D-AF46-233E40AF67B8</gtr:id><gtr:title>KIF22 coordinates CAR and EGFR dynamics to promote cancer cell proliferation.</gtr:title><gtr:parentPublicationTitle>Science signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75a150024b30ef526e738c659e188ea9"><gtr:id>75a150024b30ef526e738c659e188ea9</gtr:id><gtr:otherNames>Pike R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1945-0877</gtr:issn><gtr:outcomeId>5aa2c921e27416.70192420</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDCA1C32-F745-45A7-A9C7-92AE1938F55E</gtr:id><gtr:title>Genetic predisposition to ductal carcinoma in situ of the breast.</gtr:title><gtr:parentPublicationTitle>Breast cancer research : BCR</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d92c2578fdf05b11ca01bd9034b57626"><gtr:id>d92c2578fdf05b11ca01bd9034b57626</gtr:id><gtr:otherNames>Petridis C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1465-5411</gtr:issn><gtr:outcomeId>56d9c2a3654d08.92890326</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18500B9F-8EFA-465C-9EBA-C58AB17D22F8</gtr:id><gtr:title>What Is Direct Allorecognition?</gtr:title><gtr:parentPublicationTitle>Current transplantation reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7a487776927702f0e2714d73f629af4"><gtr:id>c7a487776927702f0e2714d73f629af4</gtr:id><gtr:otherNames>Boardman DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58b58afbd8d0d3.52549201</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB45D149-5DD7-4787-8A39-E0A80C91115C</gtr:id><gtr:title>Abnormalities in neuroendocrine stress response in psychosis: the role of endocannabinoids.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c22af857141a499f0d08af913fb600d2"><gtr:id>c22af857141a499f0d08af913fb600d2</gtr:id><gtr:otherNames>Appiah-Kusi E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>56d1fce60d21d5.61330151</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AD3965C-FAFA-4081-A036-18E43DF7310A</gtr:id><gtr:title>The effects of cannabis use on salience attribution: a systematic review.</gtr:title><gtr:parentPublicationTitle>Acta neuropsychiatrica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc2605fdf7c69ca7d4fd21f6ed02c4f9"><gtr:id>bc2605fdf7c69ca7d4fd21f6ed02c4f9</gtr:id><gtr:otherNames>Wijayendran SB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0924-2708</gtr:issn><gtr:outcomeId>58b44479c355f0.31467096</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DD5C562-D60C-4B0F-B37C-8D013EB710D7</gtr:id><gtr:title>Effect of cannabis on glutamate signalling in the brain: A systematic review of human and animal evidence.</gtr:title><gtr:parentPublicationTitle>Neuroscience and biobehavioral reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b049c6cefb2ed70ba46f4ac7d803bc76"><gtr:id>b049c6cefb2ed70ba46f4ac7d803bc76</gtr:id><gtr:otherNames>Colizzi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0149-7634</gtr:issn><gtr:outcomeId>56f2d276e3d629.79094499</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B99C7BEA-5F61-448F-878F-12A6EE7F3D66</gtr:id><gtr:title>Characterization of the resting-state brain network topology in the 6-hydroxydopamine rat model of Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a70f1e957b0b0fe76d5d7ff8299a83aa"><gtr:id>a70f1e957b0b0fe76d5d7ff8299a83aa</gtr:id><gtr:otherNames>Westphal R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5aaa4ffc5b3171.54974160</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D462A8A5-4FF3-49EB-9F95-4677FEB5888B</gtr:id><gtr:title>Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97cdb892bd28119895c5dee797659702"><gtr:id>97cdb892bd28119895c5dee797659702</gtr:id><gtr:otherNames>Galleu A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>5a900907e20542.13877548</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FDE9FC5-9302-4102-B553-B50E4A38A813</gtr:id><gtr:title>The Use of Contrast Agents in Clinical and Preclinical PET-MR Imaging.</gtr:title><gtr:parentPublicationTitle>PET clinics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b3d72485ce8a2356b14059b1925b807"><gtr:id>2b3d72485ce8a2356b14059b1925b807</gtr:id><gtr:otherNames>Sandiford L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1556-8598</gtr:issn><gtr:outcomeId>5aaa528878fc13.73110763</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00520324-DF44-45F0-A2CC-45FC0598561F</gtr:id><gtr:title>Exploiting the Metal-Chelating Properties of the Drug Cargo for In Vivo Positron Emission Tomography Imaging of Liposomal Nanomedicines.</gtr:title><gtr:parentPublicationTitle>ACS nano</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85d2cb0bd0da77681322686b7c859752"><gtr:id>85d2cb0bd0da77681322686b7c859752</gtr:id><gtr:otherNames>Edmonds S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1936-0851</gtr:issn><gtr:outcomeId>5899a646a650c8.15471822</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3150CB7-6318-4823-9433-FD7F813F5219</gtr:id><gtr:title>Human striatal response to reward anticipation linked to hippocampal glutamate levels.</gtr:title><gtr:parentPublicationTitle>The international journal of neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a4b4fe60da7aac199aa2977416b6eef"><gtr:id>0a4b4fe60da7aac199aa2977416b6eef</gtr:id><gtr:otherNames>Bossong MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1461-1457</gtr:issn><gtr:outcomeId>5aa942fb14c977.90295408</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83635786-8230-46D6-942A-4E66AB5AED2E</gtr:id><gtr:title>Prospects for immunotherapy of acute myeloid leukemia using ?d T cells.</gtr:title><gtr:parentPublicationTitle>Immunotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db1249502aac82c709192a06798e839c"><gtr:id>db1249502aac82c709192a06798e839c</gtr:id><gtr:otherNames>Halim L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1750-743X</gtr:issn><gtr:outcomeId>5899a64648ae48.32059033</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C79F399-2937-4CA7-9E5D-08109EECA992</gtr:id><gtr:title>Commentary on &amp;quot;The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis&amp;quot;.</gtr:title><gtr:parentPublicationTitle>Schizophrenia bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31467d4a8a2dee0bc64957171260598f"><gtr:id>31467d4a8a2dee0bc64957171260598f</gtr:id><gtr:otherNames>McGuire P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0586-7614</gtr:issn><gtr:outcomeId>5aa942fb329fc5.83920658</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C52F68C1-25BF-42AD-A07B-AD58928EC621</gtr:id><gtr:title>Targeting of Aberrant av?6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26df6ecbbfa25d74e3babc1f779db156"><gtr:id>26df6ecbbfa25d74e3babc1f779db156</gtr:id><gtr:otherNames>Whilding LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>5899a4ceac5473.87875979</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBA9E06E-FD4D-473D-8F46-F229727BA412</gtr:id><gtr:title>Immune modulation by apoptotic dental pulp stem cells in vivo.</gtr:title><gtr:parentPublicationTitle>Immunotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80f402ed5a658810e9f8ef86605e10f1"><gtr:id>80f402ed5a658810e9f8ef86605e10f1</gtr:id><gtr:otherNames>Laing AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1750-743X</gtr:issn><gtr:outcomeId>5a900908620382.32034888</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57F7DC73-5948-4EC4-932E-0112E4379D9C</gtr:id><gtr:title>The influence of dilution on the offline measurement of exhaled nitric oxide.</gtr:title><gtr:parentPublicationTitle>Physiological measurement</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba6353eb4ba5fed29d52cab7115acc50"><gtr:id>ba6353eb4ba5fed29d52cab7115acc50</gtr:id><gtr:otherNames>MacBean V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0967-3334</gtr:issn><gtr:outcomeId>5a8175d8635c73.21120767</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95C80ADF-74B6-41B0-B274-0ECF33C21EEE</gtr:id><gtr:title>CAR: A key regulator of adhesion and inflammation.</gtr:title><gtr:parentPublicationTitle>The international journal of biochemistry &amp; cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/efe49855dbf8663f30a436f404417a14"><gtr:id>efe49855dbf8663f30a436f404417a14</gtr:id><gtr:otherNames>Ortiz-Zapater E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1357-2725</gtr:issn><gtr:outcomeId>5a79c35e4c20a9.58114594</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEB3907F-2B9B-4F2E-9554-2321ECC58FDF</gtr:id><gtr:title>Labeling of cell therapies: How can we get it right?</gtr:title><gtr:parentPublicationTitle>Oncoimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d28dabb099cbcd327d02fdf83f74a111"><gtr:id>d28dabb099cbcd327d02fdf83f74a111</gtr:id><gtr:otherNames>Waiczies S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2162-4011</gtr:issn><gtr:outcomeId>5a900e32dca125.40885535</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F54FDB8-E715-4283-B8AA-B10049F190E2</gtr:id><gtr:title>Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/819c854adcd2b4ec203d04eb131cc753"><gtr:id>819c854adcd2b4ec203d04eb131cc753</gtr:id><gtr:otherNames>Mazur NI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn><gtr:outcomeId>58c2de822a9799.31062228</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F954B77-E116-4782-87EF-E6D84E7CD980</gtr:id><gtr:title>Modelling Radiological Language with Bidirectional Long Short-Term Memory Networks</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5f1bcbd47f5d2a56e22a1e466567704"><gtr:id>f5f1bcbd47f5d2a56e22a1e466567704</gtr:id><gtr:otherNames>Cornegruta S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58c2e01311da35.28363261</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58B3DC9A-56AA-4C25-A5D8-C43FC10D2F24</gtr:id><gtr:title>Galectin-1 is required for the regulatory function of B cells.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58ff17d77279e3959684be392b8509a3"><gtr:id>58ff17d77279e3959684be392b8509a3</gtr:id><gtr:otherNames>Alhabbab R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a90090830ceb6.68948624</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F4EDC33-33A3-4E05-8210-AD12114A672E</gtr:id><gtr:title>Gated chimeric antigen receptor T-cells: the next logical step in reducing toxicity?</gtr:title><gtr:parentPublicationTitle>Translational Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ad6f49d0ccc03aec9d1a84c4cf263c5"><gtr:id>6ad6f49d0ccc03aec9d1a84c4cf263c5</gtr:id><gtr:otherNames>Davies D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>5899ddaaf35871.94379531</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0394448-6960-427B-9397-35F051C49101</gtr:id><gtr:title>Prospects for combined use of oncolytic viruses and CAR T-cells.</gtr:title><gtr:parentPublicationTitle>Journal for immunotherapy of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/791ae9354f839046f1c8ea957935a33b"><gtr:id>791ae9354f839046f1c8ea957935a33b</gtr:id><gtr:otherNames>Ajina A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2051-1426</gtr:issn><gtr:outcomeId>5a7ae4b58b8214.67643256</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>800B6CA4-2B94-4133-97EF-611C4A13D862</gtr:id><gtr:title>Does thinner right entorhinal cortex underlie genetic liability to cannabis use?</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a95aa498ef1e03c2cdf6b5e16f600c96"><gtr:id>a95aa498ef1e03c2cdf6b5e16f600c96</gtr:id><gtr:otherNames>Paul S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>5aa942fba841b2.50653360</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A994A99F-7B41-4977-BAD1-78C0A510F426</gtr:id><gtr:title>Reduced TCR Signaling Contributes to Impaired Th17 Responses in Tolerant Kidney Transplant Recipients.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a852e087195ad0146102a9de3e4ab8b"><gtr:id>4a852e087195ad0146102a9de3e4ab8b</gtr:id><gtr:otherNames>Nova-Lamperti E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>5a900c1e093ab7.13421564</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9F7FB5B-725F-43B9-B93F-9DE9E04129E8</gtr:id><gtr:title>Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition.</gtr:title><gtr:parentPublicationTitle>Current addiction reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b049c6cefb2ed70ba46f4ac7d803bc76"><gtr:id>b049c6cefb2ed70ba46f4ac7d803bc76</gtr:id><gtr:otherNames>Colizzi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5aa942fc424d08.03783194</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A7D9331-1AD2-4C8A-B539-B6AECA837104</gtr:id><gtr:title>The Influence of DAT1, COMT, and BDNF Genetic Polymorphisms on Total and Subregional Hippocampal Volumes in Early Onset Heavy Cannabis Users.</gtr:title><gtr:parentPublicationTitle>Cannabis and cannabinoid research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dec4ddbccec588d8be966d99ba480b61"><gtr:id>dec4ddbccec588d8be966d99ba480b61</gtr:id><gtr:otherNames>Batalla A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2378-8763</gtr:issn><gtr:outcomeId>5aa942fbc77959.09691528</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_14105</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>